Patient


  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    aprott via Getty Images
    Image attribution tooltip

    Beyond the drug: Closing the knowledge gap for injectable diabetes meds

    As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs. 

    By April 22, 2025
  • A picture of a man tied to a COVID-19 virus
    Image attribution tooltip
    wildpixel via Getty Images
    Image attribution tooltip

    Genetic breakthroughs could point pharma to a long COVID drug

    The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

    By Kelly Bilodeau • April 22, 2025
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • UnitedHealthCare sign
    Image attribution tooltip
    Stephen Maturen via Getty Images
    Image attribution tooltip

    The fallout from UnitedHealth’s CEO slaying

    Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.

    By PharmaVoice staff • April 15, 2025
  • Michelle Werner, Caffrey
    Image attribution tooltip
    Permission granted by Michelle Werner
    Image attribution tooltip
    Profile

    Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

    Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

    By April 8, 2025
  • sperm pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A birth control pill for men makes moves in the clinic

    So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

    By Kelly Bilodeau • April 7, 2025
  • megaphone quieted
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With government health info in limbo, drugmakers lose credible sources

    The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

    By Alexandra Pecci • April 1, 2025
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A recent gene therapy death shines a light on AAV safety

    This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

    By Kelly Bilodeau • March 31, 2025
  • fda logo
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

    The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

    By March 28, 2025
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

    The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

    By March 20, 2025
  • Colorful medical pills cover Benjamin Franklin's face on one hundred american dollar bill.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pricing transparency is in the spotlight — and that could be good news for drugmakers

    An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

    By March 11, 2025
  • Satisfied content patient feeling happy after receiving good news from female doctor at home visit while sitting on couch.
    Image attribution tooltip

    elements.envato.com/drazenphoto

    Image attribution tooltip
    Sponsored by Noble International

    Navigating human errors in medical device usage: Insights from human factors research

    Even the most advanced medical devices can fail patients if used incorrectly. These are the most common errors.

    By Samantha Colangelo, M.S. • March 10, 2025
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    The top 3 impacts of Trump’s health data purge

    Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

    By Michael Brady • March 6, 2025
  • Pill pop art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Americans want to participate in clinical trials — so why don’t they?

    A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

    By Kelly Bilodeau • March 4, 2025
  • A doctor's appointment/consultation on your phone
    Image attribution tooltip
    Permission granted by ixlayer
    Image attribution tooltip
    Sponsored by ixlayer

    Transforming biopharma’s approach to patient engagement with direct-to-patient programs

    Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.

    By Matthew Walsh, General Manager, Biopharma, ixlayer • March 3, 2025
  • Teva
    Image attribution tooltip
    Permission granted by Teva
    Image attribution tooltip

    Teva targets schizophrenia to build on innovative medicines growth

    The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

    By Feb. 28, 2025
  • Capitol building, DC
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

    Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

    By Feb. 25, 2025
  • A sign reading Food and Drug Administration is seen above a door to a government building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    In FDA job cuts, experts see threat of far-reaching impact

    "Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

    By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025
  • young man holds smart phone and looks at orange bottle of pills blurred
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The kids are alright: How pharma can make inroads with Gen Z

    As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

    By Feb. 12, 2025
  • sleeping dream world
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Are orexins the next golden child of neuroscience?

    An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

    By Feb. 10, 2025
  • A person holds two blue drug tablets in their left hand.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip
    Deep Dive

    A new, non-opioid pain drug is here. Getting it to patients could be agony.

    After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

    By Jacob Bell • Feb. 3, 2025
  • petri dish seeds
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Year in Preview

    Pharma’s forecast for 2025: Sowing seeds of a rebound

    Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

    By Jan. 31, 2025
  • dna helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Gene therapies have been uneven for DMD — but these companies hope to turn the tide

    Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

    By Jan. 24, 2025
  • A special needs kid in a wheelchair smiling and being hugged by an adult
    Image attribution tooltip

    iStock.com/jarenwicklund

    Image attribution tooltip
    Sponsored by Accessia Health

    Beyond copays: Redefining assistance for those with rare diseases and chronic conditions

     Accessia Health helps ease the burden of managing a rare disease or chronic condition.

    Jan. 21, 2025
  • Elon Musk Capitol Hill
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

    There’s more to pharma's regulatory story in 2025 than just the IRA.

    By Jan. 17, 2025
  • 2025 pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion // Year in Preview

    PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

    Coming changes that could impact pharma from drug development to launch.

    By Jan. 10, 2025